Member Info for sadoldgit

Blocking both Tyk2 and Jak1 in this study was more effective than inhibition of Tyk2 alone at reducing psoriasis-like disease severity, keratinocyte proliferation, as well as IL-23, IL-17, IL-6, IL-22, and antimicrobial peptide gene expression, and the authors postulate that targeting a combination of Jak1 and Tyk2 ...8 Feb 2023

Effectively we will l believe be looking at a PASI score of over 75 in a 12 week period.

That is my opinion and pretty sure we will achieve this.

We are not alone as there exist promising developments of Tyk2 Jak2 in this area.

Https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9959504/#:~:text=Blocking%20both%20Tyk2%20and%20Jak1,combination%20of%20Jak1%20and%20Tyk2

Even greater post C79.

I feel we will be following with very similar footsteps.

Regards

Great Post Georgehume. Agree in its entirety.

Regards

Thanks Parrot Talk, will take on board.

Regards

Good morning Ahfam, no news is good news so it is said and regards to 1801 is the case.

6 months plus into clinical trial and all we are told is trial is going well.

Pre linical toxicity studies were carried out at over 30 times treatment dose and no adverse effects were observed.

Getting things right in preclinical will pay dividends later and is indicated here by acceleration into dose escalation did no hint of even the slightest adverse effect.

Autoimmune is indeed complicated and over half of all ailments are autoimmune related.

One of the most important aspects of the immune system is diet. Poor diet does and will lead to complications.

I have just been diagnosed with high blood sugar levels so have been actively on a strict diet. No added sugar no cakes, biscuits or chocolates, sweet drinks oh and potatoes, white rice or pasta,

I had another blood test Friday and will get result on Monday. Originally 6.1 so looking for this to have dropped slightly.

I often have thought about the contribution a healthy diet makes to overcome many diseases especially if undergoing treatment.

Back to Sareum.

All looks well with 1801 progression.

The economic climate has changed dramatically since early 2022.

The price of oil erratic at the moment. High inflation and high interest rates have a marked affect on people's disposable income.

Interestingly the US has been lifting sanctions on Venezuela and their oil production has increased. They have the largest oil reserves on the planet.

Market sentiment has had an adverse effect on the pharmaceutical industry especially AIM.

However, whilst this sentiment has reduced the market cap of companies (some close to 90%) it will not l believe reduce the value of of companies products that have potential commercialisation.

Large pharma with billions available will cherry pick to replace their patent endinding, pipeline of drugs.

1801 has the potential to be commercially extremely attractive but at the same time they will need Safety data and an indication of where 1801 can best perform. Biomarker data of extreme importance here.

The major concern l have is how Sareum intend to fund if required past the end of 2024. Do they have plans?

Maybe 737 will come into play.

All takes time, as we know.

737 at the moment an unknown quantity and hence what we have is the continued clinical trials of 1801 to go on.

45 million is peanuts for what we have, but market sentiment governs at the moment.

Regards

Not a daft question 007.

I have no idea the o ly thing that l would suggest is the compound was designed and submitted as an oral route of intake as oposed to iv.

The compound at the time could be made in small amounts suitable for laboratory use but gave problems manufacturing in clinical use whereby my larger volumes are required.

Regards.

The only one l remember is the graph from Sareum of comparison of Inhibitor in mono and inhibitor with LDG.

The good old days when this type of information was available on the Sareum website.

Interesting here is an old RNS. TYK2 related which stumbled across whilst looking at oldish news.

https://www.lse.co.uk/rns/SAR/promising-step-in-psoriasis-drug-development-yn5cm3i41fc909x.html

Regards

Thanks for posting the Interesting link PT.

Long time ago.

I was pretty certain that AML does not produce tumours too. I am wrong on that one.

'AML is usually found in the blood and bone marrow. It can sometimes spread to other parts of the body, such as the lymph nodes, spleen, liver, brain, skin, and gums. Occasionally, AML cells can form a solid tumor called a myeloid sarcoma or chloroma that can develop anywhere in the body'

Regards

That is a possibility especially at an early stage of development HbD.

Watch this space and see what evolves comes to mind.

It certainly did rise Ahfam.

1801 comes to fruition will easily surpass that increase.

Wholly Sareum created, our once Jewel in the Crown.

Funding stopped to concentrate on 737 and SDC compounds

Regards

99% certain Aurora plus FLT 3 was for acute myeloid leukemia.

Ceased development as problems with solubility via the oral route. Not that distant to early concerns with our SDC 1801 and 1802.

In this instance there exists no tumour in AML

Long time ago

Regards

As far as l can recall it was around 2013

I know no mention of it before hand.

What was it related to?

CCT245737 in combo with low dose gemcitabine.

10 out if 10 mice were never cured. 10 out of 10 mice had grater than 98% tumour reduction. 2 or 3 of the mice had no recurrence of the tumour.

A much more recent preclinical 10 out of 10 mice in combo with 737 and either Parpi or PD-1 gave 10 out 10 mice tumour reduction of which 8 had no detectable signs after 60 days. That report came about early 2019.

Final trial designs never materialised by Sierra Oncology.

The best partner l can see at the moment is Mercks new PD-1 inhibitor which has less toxicity than their previous PD-1.

Caution here is the satisfactory toxicity concerns of a ChK1 inhibitor with a PD-1 inhibitor.

Several investigative teams have carried out work in this area including or involvement with ICR.

Certainly an area that the deem worthy of further investigation.

Regards

When did the mice first come around?

I don't believe the BoD will come to the rescue as such by buying shares. They did sell some recently but they were options.

Tim and Co have enough.

There is no mass selling.

1801 doing well in dose escalation and that is what matters at the moment.

From previous comments by the BoD all is going well so clearly they know how progress is going and kept up to date.

Safety profile is of paramount importance. Most compounds come to grief on safety issues. These mostly arise when an attempt on increase of efficacy occurs by increasing daily dosing. This very much the case when looking into alternative Indications.

If we take GSK their prime objective is commercialisation of compounds. Once a compound has been approved in one indication they then look at other Indications. Hence why so many failures in late stage trials.

1801 is the only compound fully developed by Sareum to enter clinical trial.

Their 737 chk1 inhibitor worked well with what it is designed to do. A Chk1 inhibitor can only really control or limit growth of a cancer. By working at the point of cell mitosis it can never effectively in itself destroy cancerous cells, hence good results achieved in stabilising or limiting growth. Cancer cells are apoptic meaning they have no programmed cell death. Hence for 737 to work effectively it needs to be in a in combo therapy whereby the other agents can either destroy or create significant DNA damage that with the addition of a Chk1 inhibitor leads to cell death.

This was taken on in partnership with ICR.

The difference with 1801 and 1802 is these compounds are wholly developed by Sareum.

The autoimmune game us completely different in a sense. The compound can be designed to limit toxicity and at the same time be suitable to different Indications.

Deucravacitinib the allosteric TYK2 being presented as being the be all and end all in inhibitors was good in Psoriasis but failed to meet its end points in UC. Why did it fail if it were so good?

Jak1 and Jak3 inhibitors have greater success much greater success in this area but do have dose limiting side effects.

So there exists a balance, a very fine balance that attention to detail such as the make up of the 30 plus molecules involved and the compounds that are created from it. Purity of compound of vital importance as is rigorous preclinical work which many companies skimp on in an effort to get their compounds first into the clinic.

Enough from me, my investment long term. Very little different to the approach of the HNWi albeit my holding not quite as much but albeit at a much lower price.

Regards

Puma.

One thing l am not sonny is stupid!

As for being here too long? In what capacity are you to make this sort of statement?

You need to learn to grow up.

Regards

PUMA.

I am referring to pre consolidation price.

Consolidation was a factor of 50.

Hence my view sub under a pound a share is good. I am here long term.

Clearly you did not understand my previous post.

Regards

I will take advantage of adding st these prices.

Long term plan add when price is low and will sell around 50% of on news of licence deal. Long term investment as opposed to trading.

I had sold some at 9p and slighty less l admit. Maybe should have sold more. But my game plan has not changed. Buying back sub 2p is a bargain to me and l have been adding and will continue to do so.

I am more than happy for the derampers to prattle on.

Regards

Https://www.labiotech.eu/in-depth/specialized-biotech-vc-firms-funding/

Very talented lady it sounds to me Luton. Not many women do parachuting or sky diving, especially naked.

Regards